Passa al contenuto
Merck
Tutte le immagini(3)

Key Documents

479M-9

Sigma-Aldrich

MDM2 (IF2) Mouse Monoclonal Antibody

Sinonimo/i:

Mouse double minute protein 2

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203

Origine biologica

mouse

Livello qualitativo

100
500

Coniugato

unconjugated

Forma dell’anticorpo

culture supernatant

Tipo di anticorpo

primary antibodies

Clone

IF2, monoclonal

Descrizione

For In Vitro Diagnostic Use in Select Regions

Forma fisica

buffered aqueous solution

Reattività contro le specie

human

Confezionamento

vial of 0.1 mL concentrate (479M-94)
vial of 0.1 mL concentrate Research Use Only (479M-94-RUO)
vial of 0.5 mL concentrate (479M-95)
vial of 1.0 mL concentrate (479M-96)
vial of 1.0 mL concentrate Research Use Only (479M-96-RUO)
vial of 1.0 mL pre-dilute Research Use Only (479M-97-RUO)
vial of 1.0 mL pre-dilute ready-to-use (479M-97)
vial of 7.0 mL pre-dilute ready-to-use (479M-98)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (479M-98-RUO)

Produttore/marchio commerciale

Cell Marque

tecniche

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:50 (concentrated)

Isotipo

IgG

Controllo

dedifferentiated liposarcoma, well-differentiated liposarcoma

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

Visualizzazione

nuclear

Descrizione generale

Mouse double minute protein 2 (MDM2) is a gene encoded on the 12q13-14 chromosomal sequence.1-5 It encodes for a 483 amino acid residue protein which binds to the amino-terminal transcription region of p53.2,5 MDM2 has been shown to negatively regulate the tumor-suppressor activity of p53 by three mechanisms: Blocking p53 transcription, binding to p53 causing it to be exported from the nucleus, and accelerating the destruction of p53.1 MDM2 up-regulation has been shown in liposarcoma while being absent in lipoma.2,4 Therefore, anti-MDM2 has been demonstrated to be a potentially useful tool in distinguishing well-differentiated liposarcoma (atypical lipomatous tumor) from lipoma, with the neoplastic cells positive in the former lesion and negative in lipoma.2,4

Qualità

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Stato fisico

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Nota sulla preparazione

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Altre note

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Note legali

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Matthieu Bui Nguyen Binh et al.
American journal of clinical pathology, 125(5), 693-697 (2006-05-19)
MDM2 and CDK4 immunostaining can be useful adjuncts in diagnosing liposarcoma among soft tissue neoplasms. We examined the reproducibility of MDM2 and CDK4 staining between 2 laboratories and between tissue microarrays and whole tissue sections. Sixty-two soft tissue tumors were
Stanislava Uhrinova et al.
Journal of molecular biology, 350(3), 587-598 (2005-06-15)
Critical to the inhibitory action of the oncogene product, MDM2, on the tumour suppressor, p53, is association of the N-terminal domain of MDM2 (MDM2N) with the transactivation domain of p53. The structure of MDM2N was previously solved with a p53-derived
A Arici et al.
Indian journal of cancer, 50(3), 164-169 (2013-09-26)
Liposarcomas are among the most common soft tissue sarcomas in adulthood. The purpose of the study is to perform a histopathologic typing according to World Health Organization (WHO) classification of cases diagnosed with liposarcoma and to examine the difference of
P B Aleixo et al.
Journal of clinical pathology, 62(12), 1127-1135 (2009-12-01)
Well differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) have been shown to have supernumerary chromosomes with amplified sequences of the MDM2 and CDK4 genes. MDM2 and CDK4 protein overexpression have also been identified in these tumours. To investigate whether immunohistochemistry
Matthieu Bui Nguyen Binh et al.
The American journal of surgical pathology, 29(10), 1340-1347 (2005-09-15)
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) may be difficult to distinguish from benign adipose tumors and from poorly differentiated sarcomas, respectively. Genetically, they are characterized by amplification of MDM2 and CDK4 genes on chromosome 12q13-15. We examined

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.